American Portfolios Advisors’s Monopar Therapeutics MNPR Stock Holding History

American Portfolios Advisors’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-140	Closed	-$1.61K	–	3574
2022 Q2	$1.61K	Hold	140	–	–	﹤0.01%	3182
2022 Q1	$1.78K	Hold	140	–	–	﹤0.01%	3251
2021 Q4	$2.25K	Hold	140	–	–	﹤0.01%	3147
2021 Q3	$3.41K	Hold	140	–	–	﹤0.01%	2994
2021 Q2	$4.12K	Hold	140	–	–	﹤0.01%	2903
2021 Q1	$4.34K	Buy	+140	New	+$5.11K	﹤0.01%	2754

Other funds holding MNPR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

American Portfolios Advisors's MNPR Position: Q3 2022 in Review

American Portfolios Advisors sold out of Monopar Therapeutics (MNPR) in Q3 2022, closing a stake of 140 shares — an estimated $1.61K sold.

American Portfolios Advisors first reported a position in MNPR in Q1 2021 and held it in 6 quarters. The position peaked at $4.34K in Q1 2021. 10 funds tracked by Wall St. Rank hold MNPR as of Q3 2022.

American Portfolios Advisors reported no remaining Monopar Therapeutics position as of Q3 2022 after selling out during the quarter.
American Portfolios Advisors sold 140 Monopar Therapeutics shares in Q3 2022, an estimated $1.61K.
American Portfolios Advisors first reported a position in Monopar Therapeutics in Q1 2021 and held it in 6 quarters.
American Portfolios Advisors's Monopar Therapeutics position peaked at $4.34K in Q1 2021.
10 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.